Tuberculosis (TB) Program

The Tuberclosis Program

This project supports the procurement and delivery of TB commodities for the PNFP sector in Uganda, including first-line and second-line TB medicines, GeneXpert cartridges, laboratory reagents, and diagnostic supplies. The total cost is UGX 1,000,000,000 for TB medicines, UGX 2,912,000,000 for TB diagnostics annually.

The TB Donation activity supports the storage and distribution of Tuberculosis (TB) commodities for the PNFP sector in Uganda, including first-line and second-line TB medicines, GeneXpert cartridges, laboratory reagents, and diagnostic supplies as part of implementation of the Uganda national strategic plan for tuberculosis and leprosy control 2020/2021- 2024/25 whose goal is to end TB and Leprosy by 2030

Our Partners

1.1 PHC-TB

Timeline: 3rd year of implementation.

Contract Number: 72061721D00002 / 72061723F00003

Funder : Government of Uganda

Total Cost : UGX 1,000,000,000 for TB medicines, UGX 2,912,000,000 for TB diagnostics annually.

This project supports the procurement and delivery of Tuberculosis (TB) commodities for the PNFP sector in Uganda, including first-line and second-line TB medicines, GeneXpert cartridges, laboratory reagents, and diagnostic supplies. The total cost is UGX 1,000,000,000 for TB medicines, UGX 2,912,000,000 for TB diagnostics annually.

Achievements.

395 TB facilities supplied on time,
Strengthened availability of TB medicines and diagnosis across PNFP facilities.
100% utilization of funds.
Strengthened forecasting and quantification for TB commodities.
Ensured continuous availability of TB medicines and diagnostics.
Supported scale-up of GeneXpert testing capacity.
Reduced stock-outs of key TB commodities.

1.2 TB DONATIONS

Donor : Global fund and USG through the stop TB program.

This activity supports the storage and distribution of Tuberculosis (TB) commodities for the PNFP sector in Uganda, including first-line and second-line TB medicines, GeneXpert cartridges, laboratory reagents, and diagnostic supplies as part of implementation of the Uganda national strategic plan for tuberculosis and leprosy control 2020/2021- 2024/25 whose goal is to end TB and Leprosy by 2030

Achievements

Strengthened forecasting and quantification for TB commodities.
Ensured continuous availability of TB medicines and diagnostics.
Reduced stock-outs of key TB commodities.

Who We Are

JMS is the leading Private Not-for-Profit Organization (PNFP) established in 1979 by Uganda Catholic Medical Bureau (UCMB) and Uganda Protestant Medical Bureau (UPMB) as a body Corporate under the Trustees Incorporation Act (Cap 165) licensed by the National Drug Authority (NDA) of Uganda.